Provided By GlobeNewswire
Last update: Dec 27, 2023
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to develop a manufacturing process to support development of a potential live probiotic product.
NASDAQ:SYBX (2/24/2025, 11:59:42 AM)
1.4
+0.04 (+2.94%)
Find more stocks in the Stock Screener